• Invest-NL announced a €7 million investment in VectorY Therapeutics on November 11, 2026, as part of a €74.5 million funding round.
• Other participants include existing shareholders, Angelini Ventures and the European Investment Bank.
• Amsterdam-based VectorY is developing gene therapy to produce antibodies targeting proteins involved in ALS onset and progression.
• Proceeds will expand international ALS clinical research and support technology development for other neurological disorders, including Huntington's disease.
• Clinical research is focused on treatment safety and initial indications of efficacy.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Invest-NL NV published the original content used to generate this news brief on November 11, 2026, and is solely responsible for the information contained therein.